Transition of Monoclonal Antibody Bebtelovimab, 175mg from Government Supplied to the Commercial Market
Effective August 15, 2022, Eli Lilly will begin commercial distribution of bebtelovimab, 175mg. Please see guidelines for ordering and billing here.
The Office of MaineCare Services (OMS) has updated our systems to include reimbursement for this drug purchased on the commercial market. Commercially purchased drugs are currently identified by Batch ID # D534422. Please refer to Eli Lilly’s website for up-to-date information on the batch ID #’s for commercially purchased bebtelovimab 175mg.
Eli Lilly EUA Monoclonal Antibody COVID-19 Infusion Treatment-Bebtelovimab, 175mg |
|||
|
Code |
Code Description |
MaineCare Effective Date |
Rates |
|
Q0222 |
Injection, bebtelovimab, 175 mg |
08/15/22 |
$2394.00 |
|
M0222 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
08/15/22 |
$228.29 |
|
M0223 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency |
08/15/22 |
$358.39 |
|
|
|||
If you have questions about bebtelovimab 175mg, please contact your Provider Relations Specialist.
Check out our new MaineCare logo! Learn more about this logo on the About Us page of our website.
